You are here:

Sanofi-Aventis

Name SMC ID No Status Sub. Type
 
aflibercept (Zaltrap) 878/13 Not Recommended Full submission
aflibercept (Zaltrap) 878/13 Accepted Resubmission
alirocumab (Praluent) 1147/16 Restricted Full submission
cabazitaxel (Jevtana) 735/11 Not Recommended Full submission
cabazitaxel (Jevtana) 735/11 Not Recommended Resubmission
cabazitaxel (Jevtana) 735/11 Restricted Resubmission
Clopidogrel (Plavix®) 88/04 Restricted Full submission
clopidogrel 75mg tablets (Plavix) 390/07 Restricted Full submission
docetaxel (Taxotere) 659/10 Not Recommended Non submission
docetaxel (Taxotere) 481/08 Restricted Full submission
docetaxel (Taxotere) injection concentrate 333/06 Not Recommended Non submission
docetaxel 20 and mg concentrate and solvent for solution for infusion (Taxotere) 369/07 Restricted Full submission
Docetaxel 20mg, 80mg concentrate and solvent for solution for infusion, single dose vials (Taxotere®) 201/05 Accepted Full submission
Docetaxel concentrate and solvent for solution for infusion, single dose vials (Taxotere®) 209/05 Superseded Full submission
dronedarone (Multaq) 636/10 Restricted Full submission
enoxaparin (Clexane) 380/07 Accepted Full submission
fondaparinux (Arixtra) 18/02 Accepted Full submission
insulin glargine (Lantus Solostar) 456/08 Restricted Abbreviated Submission
insulin glargine (Lantus) 860/13 Restricted Abbreviated Submission
insulin glargine (Toujeo) 1078/15 Restricted Abbreviated Submission
insulin glulisine (Apidra Solostar) 457/08 Restricted Abbreviated Submission
Insulin glulisine (Apidra) 512/08 Restricted Abbreviated Submission
insulin glulisine for subcutaneous injection 100 units/ml (Apidra) 298/06 Restricted Full submission
Irbesartan (Aprovel®) 38/03 Restricted Full submission
lixisenatide (Lyxumia) 903/13 Restricted Full submission
Oxaliplatin 50mg, 100mg powder for intravenous infusion (Eloxatin®) 211/05 Accepted Full submission
rimonabant 20mg tablet (Acomplia) In Oct 2008 the EMEA recommended temporary suspension of this product. The SMC advice has been withdrawn from the website 341/07 Advice has been withdrawn from the Website Full submission

Back